Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients.
de Castilhos J, Zamir E, Hippchen T, Rohrbach R, Schmidt S, Hengler S, Schumacher H, Neubauer M, Kunz S, Müller-Esch T, Hiergeist A, Gessner A, Khalid D, Gaiser R, Cullin N, Papagiannarou SM, Beuthien-Baumann B, Krämer A, Bartenschlager R, Jäger D, Müller M, Herth F, Duerschmied D, Schneider J, Schmid RM, Eberhardt JF, Khodamoradi Y, Vehreschild MJGT, Teufel A, Ebert MP, Hau P, Salzberger B, Schnitzler P, Poeck H, Elinav E, Merle U, Stein-Thoeringer CK. de Castilhos J, et al. Among authors: bartenschlager r. Clin Infect Dis. 2022 Aug 24;75(1):185. doi: 10.1093/cid/ciac254. Clin Infect Dis. 2022. PMID: 35536665 Free PMC article. No abstract available.
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M, Schäkel U, Djuka Fokou C, Krisam J, Stermann J, Kriegsmann K, Haberbosch I, Novotny JP, Weber S, Vehreschild M, Bornhäuser M, Bullinger L, Schmitt M, Liebregts T, Dreger P, Lorenz HM, Plaszczyca A, Bartenschlager R, Müller B, Kräusslich HG, Halama N, Jäger D, Schlenk RF, Leo A, Meuer S, Weigand MA, Motsch J, Merle U, Denkinger CM, Müller-Tidow C. Janssen M, et al. Among authors: bartenschlager r. Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y. Trials. 2020. PMID: 33023671 Free PMC article.
Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera: A semi-quantitative, high throughput, microscopy-based assay expands existing approaches to measure SARS-CoV-2 specific antibody levels in human sera.
Pape C, Remme R, Wolny A, Olberg S, Wolf S, Cerrone L, Cortese M, Klaus S, Lucic B, Ullrich S, Anders-Össwein M, Wolf S, Cerikan B, Neufeldt CJ, Ganter M, Schnitzler P, Merle U, Lusic M, Boulant S, Stanifer M, Bartenschlager R, Hamprecht FA, Kreshuk A, Tischer C, Kräusslich HG, Müller B, Laketa V. Pape C, et al. Among authors: bartenschlager r. Bioessays. 2021 Mar;43(3):e2000257. doi: 10.1002/bies.202000257. Epub 2020 Dec 30. Bioessays. 2021. PMID: 33377226 Free PMC article.
Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients.
de Castilhos J, Zamir E, Hippchen T, Rohrbach R, Schmidt S, Hengler S, Schumacher H, Neubauer M, Kunz S, Müller-Esch T, Hiergeist A, Gessner A, Khalid D, Gaiser R, Cullin N, Papagiannarou SM, Beuthien-Baumann B, Krämer A, Bartenschlager R, Jäger D, Müller M, Herth F, Duerschmied D, Schneider J, Schmid RM, Eberhardt JF, Khodamoradi Y, Vehreschild MJGT, Teufel A, Ebert MP, Hau P, Salzberger B, Schnitzler P, Poeck H, Elinav E, Merle U, Stein-Thoeringer CK. de Castilhos J, et al. Among authors: bartenschlager r. Clin Infect Dis. 2022 Aug 24;75(1):e1063-e1071. doi: 10.1093/cid/ciab902. Clin Infect Dis. 2022. PMID: 34694375 Free PMC article.
Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis.
Speer C, Töllner M, Benning L, Klein K, Bartenschlager M, Nusshag C, Kälble F, Reichel P, Schnitzler P, Zeier M, Morath C, Schmitt WH, Bergner R, Bartenschlager R, Schaier M. Speer C, et al. Among authors: bartenschlager m, bartenschlager r. Ann Rheum Dis. 2022 Apr;81(4):593-595. doi: 10.1136/annrheumdis-2021-221747. Epub 2022 Jan 10. Ann Rheum Dis. 2022. PMID: 35012926 No abstract available.
Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers.
Benning L, Morath C, Bartenschlager M, Reineke M, Töllner M, Nusshag C, Kälble F, Reichel P, Schaier M, Klein K, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Speer C. Benning L, et al. Among authors: bartenschlager m, bartenschlager r. Clin Microbiol Infect. 2022 Jul;28(7):1024.e7-1024.e12. doi: 10.1016/j.cmi.2022.01.011. Epub 2022 Feb 3. Clin Microbiol Infect. 2022. PMID: 35124261 Free PMC article.
Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy.
Töllner M, Speer C, Benning L, Bartenschlager M, Nusshag C, Morath C, Zeier M, Süsal C, Schnitzler P, Schmitt W, Bergner R, Bartenschlager R, Lorenz HM, Schaier M. Töllner M, et al. Among authors: bartenschlager m, bartenschlager r. J Clin Med. 2022 Mar 21;11(6):1739. doi: 10.3390/jcm11061739. J Clin Med. 2022. PMID: 35330069 Free PMC article.
A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo.
Heuss C, Rothhaar P, Burm R, Lee JY, Ralfs P, Haselmann U, Ströh LJ, Colasanti O, Tran CS, Schäfer N, Schnitzler P, Merle U, Bartenschlager R, Patel AH, Graw F, Krey T, Laketa V, Meuleman P, Lohmann V. Heuss C, et al. Among authors: bartenschlager r. PLoS Pathog. 2022 Jun 28;18(6):e1010472. doi: 10.1371/journal.ppat.1010472. eCollection 2022 Jun. PLoS Pathog. 2022. PMID: 35763545 Free PMC article.
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJGT, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz HM, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich HG, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-Tidow C. Denkinger CM, et al. Among authors: bartenschlager r. Nat Cancer. 2023 Jan;4(1):96-107. doi: 10.1038/s43018-022-00503-w. Epub 2022 Dec 29. Nat Cancer. 2023. PMID: 36581734 Free PMC article. Clinical Trial.
437 results